StockData
Bicycle Therapeutics PLC logo

Bicycle Therapeutics PLC (BCYC) stock

BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.18−0.19 (-5.64%)

Close on Nov 16, 2026Market cap $222.90MP/E –Yield 0.00%

Bicycle Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Bicycle Therapeutics's total debt was $30.91M at Jun 30, 2024. For fiscal 2023 it was $30.70M, up 1.3% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2023Dec 31, 2023$30.70M+1.3%
FY2022Dec 31, 2022$30.32M+1.5%
FY2021Dec 31, 2021$29.87M+105.9%
FY2020Dec 31, 2020$14.51M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2024Jun 30, 2024$30.91M+1.3%
Q1 FY2024Mar 31, 2024$30.80M+1.3%
Q4 FY2023Dec 31, 2023$30.70M+1.3%
Q3 FY2023Sep 30, 2023$30.60M+1.2%
Q2 FY2023Jun 30, 2023$30.51M+1.2%
Q1 FY2023Mar 31, 2023$30.42M+1.4%
Q4 FY2022Dec 31, 2022$30.32M+1.5%
Q3 FY2022Sep 30, 2022$30.23M+1.6%
Q2 FY2022Jun 30, 2022$30.14M+1.7%
Q1 FY2022Mar 31, 2022$30.01M+1.7%
Q4 FY2021Dec 31, 2021$29.87M+105.9%
Q3 FY2021Sep 30, 2021$29.75M+106.2%
Q2 FY2021Jun 30, 2021$29.63M–
Q1 FY2021Mar 31, 2021$29.50M–
Q4 FY2020Dec 31, 2020$14.51M–
Q3 FY2020Sep 30, 2020$14.43M–

More Bicycle Therapeutics figures

See a number that looks wrong?